ACAD Dec 2025 28.000 call
| Previous close | 1.5500 |
| Open | 1.5500 |
| Bid | 0.0000 |
| Ask | 0.0000 |
| Strike | 28.00 |
| Expiry date | 2025-12-19 |
| Day's range | 1.5500 - 1.5500 |
| Contract range | N/A |
| Volume | |
| Open interest | N/A |
Business WireAcadia Pharmaceuticals is Proud to Announce the Winners of the Inaugural Rett Sibling Scholarship
SAN DIEGO, April 29, 2024--Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that it has awarded 10 academic scholarships to eligible recipients of the first Rett Sibling Scholarship. The Rett Sibling Scholarship program, sponsored by Acadia, was established in 2023 to recognize the siblings of individuals with Rett syndrome. This year’s recipients will each receive $5,000 to pursue their goals in higher education for the 2024-25 academic school year.
Simply Wall St.ACADIA Pharmaceuticals (NASDAQ:ACAD) shareholders have endured a 37% loss from investing in the stock five years ago
In order to justify the effort of selecting individual stocks, it's worth striving to beat the returns from a market...
Business WireAcadia Pharmaceuticals to Announce First Quarter Financial Results on May 8, 2024
SAN DIEGO, April 24, 2024--Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that it will report first quarter financial results on Wednesday, May 8, 2024, after the close of the U.S. financial markets. Acadia’s management team will also host a conference call and webcast on May 8, 2024, at 4:30 p.m. Eastern Time to discuss financial results and operations.
